An Increase in Plasma MicroRNA-143 Levels in the Acute Phase Is Positively Correlated With Recovery of Cardiac Function in the Chronic Phase in Patients With Acute Myocardial Infarction

Abstract

Background: MicroRNA (miR)-143 and miR-145 are non-coding RNAs present in smooth muscle cells and the heart. However, their behavior and physiological role in patients with acute myocardial infarction (AMI) have not been clarified. Methods and Results:Plasma miR-143 and miR-145 concentrations were measured on Day 0 (on admission) and on Day 7 in AMI patients who could be followed up for 6 months (n=25). The control group consisted of subjects without significant coronary stenosis (n=20). Blood samples were collected from the antecubital vein, and plasma miR-143 and miR-145 concentrations were measured by quantitative reverse transcription-polymerase chain reaction. In AMI patients (n=25), left ventricular ejection fraction (LVEF) was measured by echocardiography in the acute and chronic (6 months) phases. On Day 7, plasma miR-143 and miR-145 concentrations were significantly higher in AMI patients than in the control group and on Day 0 in AMI patients. Plasma miR-143 and miR-145 concentrations increased significantly from Day 0 to Day 7. The increase in plasma miR-143 concentrations (∆miR-143) in the acute phase was positively correlated with the increase in LVEF in the chronic phase. Among many factors, only ∆miR-143 was favorably correlated with left ventricle (LV) functional recovery in the chronic phase.Conclusions: An increase in plasma miR-143 concentrations in the acute phase may be a biomarker predicting recovery of LV function in the chronic phase in AMI patients.

Current Trends in Biohumoral Screening for the Risk of Sudden Cardiac Death: A Systematic Review

“…Regarding microRNA-143-3p, its association with acute myocardial infarction and myocardial fibrosis was found in necropsy samples [ 151 ]. Tie et al, in a recent necropsy casework study, did not observe a conclusive association between miR-143 and the risk of coronary artery disease [ 152 ], whereas Satake et al, in a follow-up MI study, concluded that miR-143 in elevated plasma concentrations in the acute phase of MI may be a predictor of left ventricular function recovery in the chronic phase [ 153 ]. Other studies that have analyzed the role of micro-RNA-143-3p have found that it has anti-oncogenic activity in metastatic proliferation from colorectal cancer [ 154 ], suppresses tumor proliferation in pancreatic ductal adenocarcinoma [ 155 ], suppresses cell growth and invasion in laryngeal squamous cell carcinoma [ 156 ], attenuates the development of liver fibrosis in autoimmune hepatitis [ 157 ], and can also be considered a biomarker of gastric cancer [ 158 ].…”

Restoration effect of chemically modified microRNA-143-3p on acute myocardial infarction in animal models

“…In the rat and rabbit AMI models, infarct sizes were analyzed three times from one shortaxis cross-sectional image at the papillary muscle level and the average value was adopted. B. Cardiac tissue miR143 levels 24 hours after the administration of 9 µg/kg miRNA (cases1-6), 9 µg/kg miR143#12 (cases [11][12][13][14][15][16][17] in the rat AMI model. Tissue miR143 levels in infarct and non-infarct areas from each case in both the control miRNA and miR143#12 groups were evaluated by qRT-PCR (at least n=3 in each).…”

“…So far, we have reported post-infarct effects of pancaspase inhibitor by using a rat AMI model 9 , and also reported that the intravenous administration of miR145 after AMI reduced myocardial infarct sizes and improved LV function in the rabbit model of AMI 10 . We recently found that increases in plasma miR143 levels during the acute phase were positively associated with LV functional recovery in the chronic phase in the patients with AMI 11 . Under these conditions, we developed a chemically modi ed miR143 called miR143#12 12 , the lipoplexed form of which was signi cantly stable in mouse blood in an in vivo experiment.…”

Plasma hsa-miR-22-3p Might Serve as an Early Predictor of Ventricular Function Recovery after ST-Elevation Acute Myocardial Infarction

“…Day of admission circulant miR-1 and miR-133a correlate positively with high-sensitivity cardiac troponin T (hsTnT) and negatively with LVEF, while the combination of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) and miR-499 identified an “at risk” group for LVR [ 22 ]. In a small group of percutaneous coronary intervention (PCI)-treated aMI patients, plasma miR-143 was found to modestly correlate with the change of LVEF at six months post-aMI [ 23 ].…”